The U.S. Department of Defense is sinking funds into a Silicon Valley initiative aimed at creating "flexible" electronics, furthering the agency's commitment to investing in innovative devices that could help soldiers on the battlefield.
Johnson & Johnson is joining forces with hardware manufacturing company PCH to launch a consumer-health focused hardware startup incubator, building on J&J's commitment to investing in early-stage companies to spur med tech innovation.
In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.
Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.
Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.
MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Japan's R-Tech Ueno, which faced a clinical setback this year in ophthalmology even as it sought wider opportunities in the area, has seen U.S.-based Sucampo launch a tender for the firm valued at $278 million overall after the founders agreed to sell their holdings.
Swedish contractor Recipharm inked a deal with Israeli biotech RedHill Biopharma to produce the company's leading drug candidate for clinical trials and an expected commercial launch.
Earlier this year, GE Healthcare CEO Jeff Immelt cited hospitals as a potentially lucrative source of growth for the company, pointing to a shift toward major contracts amid healthcare reform. Now, the company is taking a big step in that direction, inking a deal with Philadelphia's Temple University Health System to improve the medical center's radiology technology while helping it cut costs.
Sequenom has already made waves with its noninvasive prenatal diagnostic, revealing earlier this year that its technology could uncover signs of cancer in pregnant women. Now, the company is moving forward with its new liquid biopsy test, teaming up with the UC San Diego Moores Cancer Center to use its tool to monitor cancer patients and match them with a suitable therapy.